论文部分内容阅读
目的:评价六味地黄丸联合依那普利对老年糖尿病肾病的影响。方法:收集住院糖尿病肾病患者100例,按照随机数字表法分为三组:口服六味地黄丸组25例;依那普利组38例:口服依那普利5mg,2次/d;联合治疗组37例:六味地黄丸(河南宛西制药有限公司生产,国药准字Z41022128,0.38g/粒),每次8粒,每日3次口服,联合口服依那普利5mg,2次/d。对所有病例观察6周。比较三组糖化血红蛋白、空腹血糖以及C反应蛋白(CRP)和尿微量蛋白(mAlb)的水平变化。结果:三组治疗前观察指标比较,差异没有统计学意义(P>0.05);三组治疗后糖化血红蛋白、空腹血糖与治疗之前比较均没有明显变化(P>0.05),C反应蛋白(CRP)和尿微量蛋白(mAlb)均有明显下降(P<0.05);联合治疗组治疗以后C反应蛋白(CRP)、尿微量蛋白(mAlb)和六味地黄丸及依那普利组对比差异有统计学意义。结论:六味地黄丸联合依那普利治疗老年糖尿病肾病是临床有效的方法。
Objective: To evaluate the effect of Liuweidihuangwan combined with enalapril on senile diabetic nephropathy. Methods: 100 patients with diabetic nephropathy were collected and divided into three groups according to the random number table: oral administration of Liuweidihuangwan group (25 cases), enalapril group (38 cases): oral enalapril 5mg twice daily Group 37 cases: Liu Wei Di Huang Wan (Henan Wanxi Pharmaceutical Co., Ltd. production, Zhunzi Z41022128,0.38 g / tablets), each 8, 3 times a day orally, combined oral enalapril 5mg, 2 times / d . All cases were observed for 6 weeks. Three groups of glycated hemoglobin, fasting blood glucose and C-reactive protein (CRP) and urinary microalbumin (mAlb) levels were compared. Results: There was no significant difference between the three groups before treatment (P> 0.05). The levels of HbA1c and fasting plasma glucose in the three groups after treatment did not change significantly (P> 0.05), C-reactive protein (CRP) And mAlb (all P <0.05). The difference of CRP, mAlb, and Liuweidihuang Pill and enalapril group after treatment in the combination therapy group was statistically significant significance. Conclusion: Liuweidihuangwan combined enalapril treatment of diabetic nephropathy in elderly patients is a clinically effective method.